Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?"

We thank Baklouti et al. (1) for commenting on our population pharmacokinetic study of dalbavancin for optimal treatment of adult patients with staphylococcal osteoarticular infections (2) and for suggesting that our model tends to underestimate the concentrations observed in a group of French patients (French group).….